Abstract:Background. Prostate cancer (PC) is one of the most critical cancers affecting men’s health worldwide. The development of many cancers involves dysregulation or mutations in key transcription factors. This study established a transcription factor-based risk model to predict the prognosis of PC and potential therapeutic drugs. Materials and Methods. In this study, RNA-sequencing data were downloaded and analyzed using The Cancer Genome Atlas dataset. A total of 145 genes related to the overall survival rate of PC patients were screened using the univariate Cox analysis. The Kdmist clustering method was used to classify prostate adenocarcinoma (PRAD), thereby determining the cluster related to the transcription factors. The support vector machine-recursive feature elimination method was used to identify genes related to the types of transcription factors and the key genes specifically upregulated or downregulated were screened. These genes were further analyzed using Lasso to establish a model. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were used for the functional analysis. The TIMER algorithm was used to quantify the abundance of immune cells in PRAD samples. The chemotherapy response of each GBM patient was predicted based on the public pharmacogenomic database, Genomics of Drug Sensitivity in Cancer (GDSC, http://www.cancerrxgene.org). The R package “pRRophetic” was applied to drug sensitivity (IC50) value prediction. Results. We screened 10 genes related to prognosis, including eight low-risk genes and two high-risk genes. The receiver operating characteristic (ROC) curve was 0.946. Patients in the high-risk score group had a poorer prognosis than those in the low-risk score group. The average area under the curve value of the model at different times was higher than 0.8. The risk score was an independent prognostic factor. Compared with the low-risk score group, early growth response-1 (EGR1), CACNA2D1, AC005831.1, SLC52A3, TMEM79, IL20RA, CRACR2A, and FAM189A2 expressions in the high-risk score group were decreased, while AC012181.1 and TRAPPC8 expressions were increased. GO and KEGG analyses showed that prognosis was related to various cancer signaling pathways. The proportion of B_cell, T_cell_CD4, and macrophages in the high-risk score group was significantly higher than that in the low-risk score group. A total of 25 classic immune checkpoint genes were screened out to express abnormally high-risk scores, and there were significant differences. Thirty mutant genes were identified; in the high- and low-risk score groups, SPOP, TP53, and TTN had the highest mutation frequency, and their mutations were mainly missense mutations. A total of 36 potential drug candidates for the treatment of PC were screened and identified. Conclusions. Ten genes of both high-and low-risk scores were associated with the prognosis of PC. PC prognosis may be related to immune disorders. SPOP, TP53, and TTN may be potential targets for the prognosis of PC.

Single-nucleotide Polymorphisms of Stemness Genes Predicted to Regulate RNA Splicing, Microrna and Oncogenic Signaling Are Associated with Prostate Cancer Survival.

A Genetic Polymorphism In Pre-Mir-27a Confers Clinical Outcome Of Non-Small Cell Lung Cancer In A Chinese Population

Relationship Between Cancer Stem Cell-Related SNPs and Survival Outcomes in Patients with Primary Lung Cancer

Comprehensively Analysis of Splicing Factors to Construct Prognosis Prediction Classifier in Prostate Cancer.

Associations Between RNA Splicing Regulatory Variants of Stemness‐related Genes and Racial Disparities in Susceptibility to Prostate Cancer

Identification and validation of regulatory SNPs that modulate transcription factor chromatin binding and gene expression in prostate cancer

Cancer Stem Cell Gene Variants Predict Disease Recurrence in Patients Treated with Radical Prostatectomy for Prostate Cancer

Gene Expression Biomarkers to Predict Overall Survival of Prostate Cancer Patients

Abstract A3: MicroRNA-related Polymorphisms Are Associated with Clinical Outcomes in Early Stage Non-Small Cell Lung Cancer Patients

Potentially functional polymorphisms in DNA repair genes and non-small-cell lung cancer survival: a pathway-based analysis.

Identification of novel SNPs associated with risk and prognosis in patients with castration-resistant prostate cancer

Genetic Variants of the Wnt Signaling Pathway As Predictors of Aggressive Disease and Reclassification in Men with Early Stage Prostate Cancer on Active Surveillance.

Identification of a Novel Stemness-Related Signature with Appealing Implications in Discriminating the Prognosis and Therapy Responses for Prostate Cancer

Systematic Profiling of Alternative Splicing Signature Reveals Prognostic Predictor for Prostate Cancer

Combined CRISPRi and Proteomics Screening Reveal a Cohesin-Ctcf-bound Allele Contributing to Increased Expression of RUVBL1 and Prostate Cancer Progression

Comprehensive Analysis of Alternative Splicing Profiling Reveals Novel Events Associated with Prognosis and the Infiltration of Immune Cells in Prostate Cancer.

Genetic Variants in Epithelial-Mesenchymal Transition Genes As Predictors of Clinical Outcomes in Localized Prostate Cancer.

Polymorphisms of the stem cell marker gene CD133 are associated the clinical outcome in a cohort of Chinese non-small cell lung cancer patients

Correlation Between Prostate Stem Cell Antigen Gene Expression and Oral Squamous Cell Carcinoma.

Prognostic Assessment of Apoptotic Gene Polymorphisms in Non-Small Cell Lung Cancer in Chinese

A Transcription Factor-Based Risk Model for Predicting the Prognosis of Prostate Cancer and Potential Therapeutic Drugs